Clinical Trials
8
6 active
Approvals
4
Total approvals
Agencies
1
Regulatory bodies
Founded
1990
Active, not recruiting
6
75.0%
Recruiting
2
25.0%
- Kamada Ltd. announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, the gold standard for measuring rabies-neutralizing antibodies. - The new laboratory will support quality control testing for KEDRAB and KAMRAB manufacturing, representing over $70 million in sales for 2025. - The facility enables increased operational efficiencies and reduces reliance on external testing while meeting stringent safety, quality and GMP standards. - The laboratory is located in Kamada's Beit Kama, Israel plant and is one of a limited number of facilities worldwide capable of performing such specialized tests.
- Kamada Ltd. received FDA approval for its San Antonio plasma collection center following a February 2026 inspection, clearing the facility to commence commercial sales of normal source plasma. - The 11,100 square foot facility supports up to 50 donor beds with an annual collection capacity of approximately 50,000 liters and projected revenues of $8-10 million at full capacity. - The center is designed to collect both normal source plasma and specialty plasma including anti-rabies and anti-D products, positioning it as one of the largest specialty plasma collection centers in the United States. - Kamada now operates three FDA-approved plasma collection centers in Texas, significantly expanding its capacity for specialty and normal source plasma collection to support its portfolio of rare disease treatments.
- Kamada Ltd. received FDA approval for its Houston plasma collection center following a second quarter 2025 inspection, clearing the facility to commence commercial sales of normal source plasma. - The 12,000 square foot facility features 50 donor beds with an annual collection capacity of approximately 50,000 liters and projected revenue contribution of $8-10 million at full capacity. - The Houston center is anticipated to become one of the largest specialty plasma collection sites in the U.S., collecting both normal source plasma and specialty plasma including anti-rabies and anti-D products. - Combined with existing facilities in Beaumont and San Antonio, Texas, Kamada now operates three plasma collection centers to support its portfolio of FDA-approved plasma-derived therapies for rare conditions.
